back to

Back to video list

Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

Speaker

Kara Kelly

Session

Pediatric and Adolescent Treatment Concepts

Others Talks of this Session

Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective
Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective
Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization
EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY
Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)